Abstract: A device receives an image. The image is applied to a sequence of encoders that includes a first encoder and one or more subsequent encoders, each including a U network encoder which performs convolution neural network processing. The one or more subsequent encoders receive a down-sampled version of the image from a prior encoder. The sequence of encoders form a first dimension orthogonal to the orthogonal dimension. A result of the sequence of encoders is applied to a sequence of decoders that includes a first decoder and one or more subsequent decoders. A respective decoder comprises a U network decoder that performs convolution neural network processing of an up-sampled version of the image from the first decoder. Probability outputs are produced from paired encoders and decoders in the sequence of encoders and the sequence of decoders. The probability outputs are combined to form a final output.

Abstract: A non-transitory computer readable storage medium has instructions executed by a processor to receive an ultrasound image. The ultrasound image is applied to a sequence of encoders where each encoder in the sequence of encoders performs convolution neural network processing of a down-sampled version of the ultrasound image from a prior encoder, the sequence of encoders form a first dimension. The ultrasound image is applied to a transition encoder with an orthogonal dimension to the first dimension. The ultrasound image is applied to a sequence of decoders where each decoder in the sequence of decoders performs convolution neural network processing of an up-sampled version of the ultrasound image from a prior decoder, the sequence of decoders form a second parallel dimension to the first dimension. Encoder and decoder configurations and the first dimension, the orthogonal dimension and the second parallel dimension thereby define a nested U network architecture.

Abstract: A non-transitory computer readable storage medium has instructions executed by a processor to receive an ultrasound image. The ultrasound image is applied to a sequence of encoders where each encoder in the sequence of encoders performs convolution neural network processing of a down-sampled version of the ultrasound image from a prior encoder, the sequence of encoders form a first dimension. The ultrasound image is applied to a transition encoder with an orthogonal dimension to the first dimension. The ultrasound image is applied to a sequence of decoders where each decoder in the sequence of decoders performs convolution neural network processing of an up-sampled version of the ultrasound image from a prior decoder, the sequence of decoders form a second parallel dimension to the first dimension. Encoder and decoder configurations and the first dimension, the orthogonal dimension and the second parallel dimension thereby define a nested U network architecture.

Abstract: The present invention encompasses compositions and methods for regulating the kynurenine to tryptophan ratio, NAD+ level and CD16 expression for the treatment diseases.

Abstract: The present invention encompasses compositions and methods for regulating the kynurenine to tryptophan ratio, NAD+ level and CD16 expression for the treatment diseases.

Abstract: The invention features peptide fragments containing domain 4 of the Streptococcus intermedius intermedilysin (ILY) protein and the use of these fragments to sensitize cancer cells to antibody-based anticancer treatments. The invention also features use of these fragments to treat patients infected with microbial pathogens expressing CD59 or CD59-like molecules. CD59 receptor activity has been associated with decreased sensitivity to therapeutic and endogenously produced antibodies. Administration of ILY domain 4 polypeptides is sufficient to inhibit CD59 receptor activity while avoiding the general toxicity associated with full length ILY.

Abstract: The invention features proteins including an antibody, or functional derivatives thereof, that bind hCD59 and have the activity of domain 4 of the Streptococcus intermedins intermedilysin (ILY) protein. In order to prevent the independent induction of CDC and ADCC, the antibodies of the invention can bind the same hCD59 epitope as ILYd4 and/or contain modifications that disrupt the interaction between the antibody and complement.

Abstract: The invention features proteins including an antibody, or functional derivatives thereof, that bind hCD59 and have the activity of domain 4 of the Streptococcus intermedins intermedilysin (ILY) protein. In order to prevent the independent induction of CDC and ADCC, the antibodies of the invention can bind the same hCD59 epitope as ILYd4 and/or contain modifications that disrupt the interaction between the antibody and complement.

Abstract: The invention features peptide fragments containing domain 4 of the Streptococcus intermedius intermedilysin (ILY) protein and the use of these fragments to sensitize cancer cells to antibody-based anticancer treatments. The invention also features use of these fragments to treat patients infected with microbial pathogens expressing CD59 or CD59-like molecules. CD59 receptor activity has been associated with decreased sensitivity to therapeutic and endogenously produced antibodies. Administration of ILY domain 4 polypeptides is sufficient to inhibit CD59 receptor activity while avoiding the general toxicity associated with full length ILY.

Abstract: The invention features peptides containing domain 4 of the Streptococcus intermedius intermedilysin (ILY) protein and fragments thereof, and the use of these peptides to sensitize cancer cells to antibody based anticancer treatments. CD59 receptor activity has been associated with a decreased sensitivity to therapeutic antibodies. Desirably, administration of ILY domain 4 polypeptides is sufficient to inhibit CD59 receptor activity while avoiding the general toxicity associated with full length ILY.